Evicenter
MarkdownMedical informationP&T meetings

Ersodetug (RZ358)

Tumor hyperinsulinism

Manufacturer
Rezolute
Launch
Not announced
Last updated
140 sources

Section 2 of 6

Executive summary

9 evidence topics · 37 sources

Clinical benefits of Ersodetug

Burden of Tumor hyperinsulinism

Summary: incidence and prevalence
  • Population-based incidence of insulinoma was 0.6 per million adults per year in Finland from 1980 to 2010 (0.9 per million per year in the 2000s), 1.3 cases per million per year in Western Sweden from 2002 to 2019, 4 cases per 1 million person-years in Olmsted County, Minnesota, during the last 2 decades of the study period, and 3.27 (95% CI, 2.93-3.61) per million adults per year in a Japanese national inpatient database in 2012. A clinical review reports a range of 0.7 to 4 cases per million per year.
  • Malignant or metastatic disease made up 14% (malignant) and 11% (distant metastases) of 79 Finnish cases, 16% (metastatic) of 37 Swedish cases, and 5.8% (malignant) of the 224 Mayo Clinic cases. A review places 10% to 15% of insulinomas in the aggressive category. The crude annual incidence of malignant insulinoma in the SEER registries from 1973 to 2015 (121 patients) ranged from 0.0 to 0.27 cases per million person years.
  • A Japanese nationwide survey of patients treated in 2017 to 2018 identified 205 patients with insulinoma (118 benign, 18 malignant, 69 unknown subtype) and estimated a prevalence of 0.16 per 100,000 population.
  • No population-based study of non-islet cell tumor hypoglycemia (NICTH) was identified. A systematic review cites an incidence rate of one per million person-years and estimates NICTH to be four times less prevalent than insulinoma.
  • The manufacturer estimates the U.S. “immediately addressable incidence market” for tumor hyperinsulinism at approximately 3,000 patients per year (Form 10-K, September 2026) and approximately 4,000 patients per year (Form 10-Q, November 2026), and gives a point-in-time prevalence as of October 2026 of about 2,500 malignant insulinoma and about 1,500 NICTH patients from a claims database.
Summary: survival and mortality
  • A review reports 5-year survival of 94% to 100% for indolent insulinoma and 24% to 67% for aggressive insulinoma.
  • In a Finnish nationwide cohort, median overall survival with non-metastatic insulinoma was 27.5 years and did not differ significantly from matched controls (33.2 years; HR 1.5, P = 0.128); with metastatic insulinoma it was 3.4 years (HR 5.1, P = 0.001). Perioperative mortality was 2.7%.
  • In the Mayo Clinic cohort, survival with malignant insulinoma was 29% at 10 years postoperatively against 88% expected. At one institution, 5-year overall survival was 66.8% for 51 patients with malignant insulinoma and 95.4% for 260 patients with benign insulinoma.
  • In the SEER malignant insulinoma cohort, median overall survival was 143 months, with 5- and 10-year overall survival of 58% and 55%, and 5-year overall survival was 84% with surgery and 14% without. In an Italian series of 31 patients with malignant insulinoma, 5-year survival was 62%.
  • In a systematic review of published NICTH cases with outcomes (n = 223), the recovery rate was 77% and mortality 23%.
Summary: morbidity, quality of life, and resource use
  • Compared with matched controls, Finnish insulinoma patients had a higher long-term incidence of atrial fibrillation (rate ratio 2.07) and intestinal obstruction (rate ratio 18.65). In a Japanese nationwide survey, neurological impairment was present in 22 patients (10.7%) with insulinoma (seven with dementia, seven with epilepsy), diabetes followed pancreatectomy in 25 patients (15.8%), and impaired quality of life was reported in 9 of 29 patients with residual hypoglycemia. Before surgery, 18 of 34 patients (53%) screened positive for cognitive impairment in one prospective study.
  • In the published expanded access series of refractory malignant insulin-secreting tumors, 6 of 8 individuals were hospitalized at entry (median, 28 days; range, 4-66 days), 4 had an ECOG score of 3, and 2 were under hospice consideration. The manufacturer states that tumor-directed therapies were often deferred because of debilitating hypoglycemia.
  • Patients surgically cured of insulinoma had a mean 15D score of 0.930 against 0.903 in the general population a median of 13 years after surgery. No quality of life data were identified for NICTH.
  • No cost-of-illness or claims-based cost study of insulinoma or NICTH was identified. Reported resource use includes hospital stays of 11.1 days after surgical resection and 3.0 days after endoscopic ultrasound-guided radiofrequency ablation, and an average postoperative stay of 9 days in a single-center series.

Ersodetug efficacy and safety

Summary: upLIFT phase 3 trial, preliminary results
  • upLIFT is a single-arm, open-label trial in 16 adults with uncontrolled hypoglycemia caused by tumor hyperinsulinism (12 with malignant insulinomas and 4 with non-islet cell tumors) who receive ersodetug 9 mg/kg weekly for 8 weeks as an add-on to standard of care. The primary endpoint is the proportion of participants who achieve at least a 50% reduction from baseline in glucose infusion rate within the 8-week pivotal phase; statistical significance requires the lower bound of the 95% confidence interval to exceed 30%, which equates to at least 9 responders.
  • In preliminary results announced on 13 November 2026, 13 participants had met the responder criterion, including 12 who also achieved complete discontinuation of IV glucose. Three participants remained in the pivotal period, including 2 who had not yet met the criterion. One participant with stage 4 metastatic colon cancer and ECOG 4 status withdrew to home hospice and died one week later from cancer progression, and is counted as a non-responder.
  • The manufacturer states that the results are preliminary and may change upon completion of the study, and reports no drug-related safety findings attributed to ersodetug in the pivotal and extension phases.
Summary: expanded access in tumor hyperinsulinism
  • A retrospective case series reports 8 adults with refractory hypoglycemia (metastatic insulinoma, 7; cervical neuroendocrine carcinoma, 1) treated with ersodetug under compassionate use. Six of 7 individuals on parenteral glucose discontinued it within 90 days (median, 4.5 days). Percent time below 70 mg/dL by continuous glucose monitoring fell from a mean of 12.4% to 8.0% (median absolute change −3.8%; 90% CI, −8.2 to −1.1), and the mean number of antihypoglycemic therapies fell from 3.8 to 1.6. All 6 hospitalized individuals were discharged (median, 9 days; range, 1-84), and 7 proceeded to tumor-directed therapy within 8 weeks. The authors report nominal P-values with no prespecified hypothesis testing.
  • Company presentations of 9 patients report that 7 of 8 patients receiving parenteral glucose at baseline achieved at least a 50% reduction, and that 75% of patients receiving IV dextrose or parenteral nutrition discontinued it completely.
  • No drug-related serious adverse events occurred in the case series; 3 of 8 individuals had serious adverse events, all attributed to tumor progression or tumor-directed therapies. Six individuals died, with tumor progression and sepsis cited as causes.
Summary: supporting trials in congenital hyperinsulinism and healthy volunteers
  • sunRIZE, a randomized, double-blind, placebo-controlled phase 3 trial in congenital hyperinsulinism, did not meet its primary endpoint: weekly hypoglycemia events by self-monitored blood glucose fell by approximately 45% at 10 mg/kg and by 40% with placebo. It did not meet its key secondary endpoint: percent time in hypoglycemia by continuous glucose monitoring fell by approximately 25% at 10 mg/kg and rose by approximately 5% with placebo (congress presentation: −32%, p=0.30). After reviewing the data, the FDA encouraged a pre-BLA meeting for congenital hyperinsulinism and did not opine on approvability; the manufacturer states that the FDA may require another study similar to sunRIZE, and that it has asked the FDA whether the sunRIZE results will affect the assessment of ersodetug in tumor hyperinsulinism.
  • RIZE, an open-label phase 2 study in 23 participants with congenital hyperinsulinism aged 2 years and older who received 3 to 9 mg/kg for 8 weeks, was not powered for its endpoints. Hypoglycemia events by self-monitored blood glucose and time in hypoglycemia by continuous glucose monitoring improved from baseline by medians of 59% and 54% (p < 0.001) across pooled doses; the improvements did not translate to a similar improvement in time in range (70–180 mg/dL), the registry primary endpoint.
  • In 29 healthy adult males given single ascending doses, ersodetug showed dose-proportional pharmacokinetics with a half-life of 21 days, was well tolerated, and reduced insulin sensitivity in a dose-dependent manner.
Summary: safety across the clinical trials
  • Ersodetug has no prescribing information. Serious hypersensitivity reactions led to early discontinuation in 2 sunRIZE participants (topline release); a later congress presentation reports hypersensitivity leading to discontinuation in 3 participants, 2 with serious allergic reactions including anaphylaxis, and an overall incidence of approximately 2% across the clinical trials.
  • Hypertrichosis was reported in about 35% (congress presentation) or 36% (n=14, January 2026 presentation) of ersodetug-treated sunRIZE participants, was described as mild and not dose-dependent, and led to discontinuation in 1 participant. Adverse events occurred in about 90% of sunRIZE participants at a comparable rate across groups. No clinically relevant hyperglycemia and no hepatic signal by liver enzymes or ultrasound were reported.
  • In RIZE there were no deaths, adverse drug reactions, or discontinuations due to adverse events; 3 serious adverse events were judged unrelated to study drug, and 1 of 23 participants had low-titer anti-drug antibodies.
  • Liver findings in Sprague Dawley rats led to partial clinical holds on the congenital hyperinsulinism studies; the FDA removed the holds in September 2024, concluding that the toxicity is likely strain-specific and not otherwise relevant to humans. No drug interaction, pregnancy, or lactation data were identified.

Budget impact of Ersodetug

Summary
  • Ersodetug is investigational and has no published price, and no budget impact model, cost-effectiveness analysis, or health technology assessment of ersodetug has been published.
  • The manufacturer estimates the U.S. eligible population at approximately 3,000 or approximately 4,000 patients per year (incidence) and about 2,500 malignant insulinoma plus about 1,500 NICTH patients (point-in-time prevalence as of October 2026), and assumes 9 vials per infusion and 117 vials per patient per year at the 9 mg/kg maintenance dose.
  • In the manufacturer's claims data, the primary payer was Medicare for 48.6% of patients, commercial insurance for 43.9%, Medicaid for 5.5%, and other payers for 2.0%. Its payer research anticipates prior authorization with a step through diazoxide for insulinoma and reimbursement through a J-code.

Conclusions

Summary
  • Tumor hyperinsulinism comprises insulinoma, with a population-based incidence of 0.6 to 4 cases per million per year in the studies identified, and non-islet cell tumor hypoglycemia, for which no population-based estimate exists. Survival is reduced in metastatic or malignant insulinoma (median 3.4 years with metastases in a Finnish nationwide cohort), and refractory hypoglycemia in these patients is associated with prolonged hospitalization and deferral of tumor-directed therapy.
  • Current therapies have documented limitations: surgery is curative for most localized insulinomas but carries operative morbidity, diazoxide and somatostatin analogs control hypoglycemia in a proportion of patients with insulinoma and are described as ineffective in NICTH, and tumor-directed therapies for malignant disease do not directly treat hypoglycemia according to the manufacturer.
  • The efficacy evidence for ersodetug in tumor hyperinsulinism consists of preliminary, unpublished results from the single-arm, open-label upLIFT trial (13 responders among 16 participants, with at least 9 required for statistical significance; final results pending) and a retrospective case series of 8 individuals with no control group. The randomized sunRIZE trial in congenital hyperinsulinism did not meet its primary or key secondary endpoint.
  • The safety data come mostly from the congenital hyperinsulinism trials and include serious hypersensitivity reactions (overall incidence approximately 2% across the clinical trials) and hypertrichosis (about 35% of ersodetug-treated sunRIZE participants). No drug-related serious adverse events were reported in the tumor hyperinsulinism case series or, to date, in upLIFT.
  • Ersodetug is investigational, with a biologics license application planned for mid-2027, and has no price; no budget impact model or economic evaluation has been published.